Castor Appoints Dr. Ben Cons as Chairman of the Supervisory Board

Publisher: The Insight Partners

Castor, a health-tech company that aims to leverage machine readable data to increase clinical trial efficiency, announced the appointment of Ben Cons, PhD as Chairman of its Supervisory Board. Dr. Cons joins an existing Board of seasoned executives and specialist investors.

Dr. Cons has more than 30 years' experience in pharmaceutical R&D and commercialization in the biotech, pharmaceutical and financing sectors. A prominent leader in global healthcare and technology, Dr. Cons has 20 years of experience with the NYSE-listed pharmaceutical services company IQVIA and its associated investment fund NovaQuest. Currently, Dr. Cons is a Special Partner at the private equity fund Vitruvian, and a NED at Talking Medicines Ltd, Fluidic Analytics Ltd, and Immune Regulation Ltd. He is also an investment member of private capital group, 24Haymarket and an investment panel member at Future Care Capital, a charity focusing on future health and social care policy.

He joins Supervisory Board members Corné Jansen, Partner at INKEF Capital, Mark Slaughter, founder of Cohealo and Commercial Head of Pharma Solutions at Philips, and Thijs Cohen Tervaert, Director at INKEF Capital – all working in partnership with Castor's management team to continue its global growth, with the aim of making the world's research data reusable, enabling AI-driven clinical trials, and ultimately creating a future in which they maximize the impact of data through reuse.

Castor's Electronic Data Capture (EDC) platform enables every researcher worldwide to easily capture and integrate medical research data from any source in real-time, including clinicians, patients, devices and wearables. Researchers on the platform generate vast amounts of data from traditional and decentralized trials, and Castor recently reached milestones of 110,000,000 data points and 1,300,000 enrolled patients.